Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
Study Details
Study Description
Brief Summary
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The investigators primary goal is to assess the correlation of gut symptoms from various disease states with the dysbiosis of the small intestinal microbiome and metabolites collected by the SIMBA capsule, and as identified and measured by metagenomic sequencing and/or metabolomics approaches. The process consists of ingestion and collection of up to 4 SIMBA capsules, on up to 2 separate occasions, along with collection of a stool sample at the same time. Participants will also fill out a series of questionnaires on medical history and lifestyle inputs (eg. diet, exercise, mental health) GI symptoms, anxiety, and depression. The investigators ultimate goal will be to develop a better understanding of how the small intestinal microbiome might play a role in symptom generation, to establish whether the SIMBA capsule can find a signature of dysbiosis which can be used as a biomarker for a number of functional gut disorders.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Healthy Not belonging to the other cohorts as described below. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
| Irritable Bowel Syndrome As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
| Crohns Disease As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
| Ulcerative Colitis As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
| Celiac Disease As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
| Functional Dyspepsia As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied. |
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
|
Outcome Measures
Primary Outcome Measures
- Correlation of bacterial composition with gastrointestinal disease states as assessed by PLS-DA mapping. [baseline, pre-procedure]
The bacterial composition of healthy control fluid biopsy is compared to the bacterial composition of participants with diagnosed gastrointestinal diseases, to aid in gastrointestinal disease biomarker discovery.
Secondary Outcome Measures
- Correlation of bacterial composition with dietary intake as assessed by PLS-DA mapping. [baseline, pre-procedure]
Fluid biopsy bacterial composition correlated with self-reported long-term and short-term preferred variations in intake of dietary fiber and organic food.
Other Outcome Measures
- Usability of SIMBA capsule in various disease states as assessed by SIMBA-experience questionnaires. [immediately after the procedure]
Participant feedback on SIMBA capsule usage experience will inform usability data.
- Comparison of SIMBA fluid biopsy microbial composition to stool microbial composition as assessed by 16s rRNA metagenomic analysis. [baseline, pre-procedure]
- Correlations of bacterial composition with anxiety (GAD-7) scores as assessed by PCoA mapping, alpha and beta diversity analysis. [baseline, pre-procedure]
- Correlations of bacterial composition with depression (PHQ-8) scores as assessed by PCoA mapping, alpha and beta diversity analysis. [baseline, pre-procedure]
- Correlations of bacterial composition with self-reported lifestyle behaviours as assessed by PCoA mapping, alpha and beta diversity analysis. [baseline, pre-procedure]
- Number of participants with device-related adverse events as assessed by an independent Data Safety Monitoring Board. [through study completion, an average of 8 days]
- Evaluate the usability of excreted SIMBA Capsule retrieval procedures as assessed by retrieval-experience questionnaire feedback. [immediately after the procedure]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged between 18 and 80 years.
-
No previous diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, Functional Dyspepsia by participant self-report (Control group).
-
Prior diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, or Functional Dyspepsia by a relevant physician, nutritionist, naturopath, etc, and willingness to provide documentation to confirm this diagnosis or have a consultation with the PI. (Disease group).
-
Ability to understand and provide informed consent.
-
Ability and willingness to meet the required schedule, study interventions, and questionnaire requirements.
-
No planned change in diet or medical interventions during the study duration.
Exclusion Criteria:
-
Known disease which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable). The main deciding factor would be a history of obstructive symptoms in the previous 3 months prior to entry.
-
Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA) (Control Group only).
-
History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule.
-
Females of childbearing age who are pregnant or lactating by self-report. (should an X-ray be required for confirmation of capsule passage, a urine pregnancy test will be administered beforehand).
-
No antibiotics, or colon cleanses/bowel prep for 2 weeks.
-
< 2 bowel movements per week (Control Group only).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nimble Science | Calgary | Alberta | Canada | T2P 3P2 |
Sponsors and Collaborators
- Nimble Science Ltd.
Investigators
- Principal Investigator: Chris Andrews, MD, Nimble Science Ltd.
- Principal Investigator: Matthew Woo, MD, Nimble Science Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HREBA.CTC-22-0096